'ROCK' off: Study establishes molecular link between genetic defect and heart malformation

February 6, 2012
This is a single cell carrying a Noonan syndrome-associated mutation in which cell adhesion and cell shape changes have been rescued (as shown in green). Credit: Joan M. Taylor and Frank L. Conlon, UNC-Chapel Hill.

UNC researchers have discovered how the genetic defect underlying one of the most common congenital heart diseases keeps the critical organ from developing properly. According to the new research, mutations in a gene called SHP-2 distort the shape of cardiac muscle cells so they are unable to form a fully functioning heart.

The study also shows that treatment with a drug that regulates cell shape rescues the cardiac defect, pointing to therapeutic avenues that could one day benefit Noonan syndrome patients. The results, which were produced in a frog model of the disease, appeared online January 25, 2012, in the journal Development.

have shown that SHP-2 plays a critical role in and disease. Interestingly, different mutations in different portions of SHP-2 result in three different diseases – Noonan syndrome, a severe congenital disease; juvenile myelo-monocytic leukemia, a lethal form of cancer; and Leopard syndrome, a rare condition with skin, facial and cardiac abnormalities. This observation has intrigued a number of researchers, including senior study author Frank Conlon, PhD.

"I've wondered how it is that one mutation gives and doesn't affect your white blood cells, and another will wipe out your white blood cells and leave your heart alone," said Conlon, an associate professor of genetics and a member of the UNC McAllister Heart Institute. He and others have explored this mystery by creating transgenic animals -- fruit flies, mice, or in Conlon's case, frogs -- that possess a mutated form of SHP-2.

When Conlon and his team genetically engineered frogs to contain the very same defects seen in humans with Noonan syndrome, they found that the frogs did in fact develop cardiac defects. But when they created them with a mutation seen in humans with leukemia, there were no heart defects. The researchers then performed 3D modeling on the animals to assess the nature of the anatomical defects, and discovered that actin filaments – proteins responsible for giving structure to the -- were the ones affected.

Conlon and his collaborator Joan Taylor, PhD, an associate professor of pathology and laboratory medicine at UNC, then tested whether they could reverse the heart malformation using a drug called fausidil that had been shown to improve cardiac function in animal models of heart failure. The drug blocks a protein called ROCK that resides in the same neighborhood – or pathway – of intracellular processes as SHP-2.

The researchers dissolved the drug in the mutant frogs' water tank and found that it did correct the cardiac defects. Their findings connect the dots between Noonan syndrome's underlying and the resulting cardiac malformations.

"The human mutations could have been linked to anything, proliferation or cell death, and what this study does is it links it to changes, which are mediated by this important molecule ROCK," said Conlon. "Our lab studies heart development and heart disease, so we are interested in how this one set of specifically target that one organ. Why the heart? We still have to figure that out."

Related Stories

Recommended for you

Multifaceted genetic impact of training

September 23, 2016

Endurance training changes the activity of thousands of genes and give rise to a multitude of altered DNA-copies, RNA, researchers from Karolinska Institutet report. The study, which also nuances the concept of muscle memory, ...

Controlling cell-fate decisions

September 23, 2016

Rafal Ciosk and his group at the FMI have identified an important link between the Notch signaling pathway and PRC2-mediated gene silencing. They showed that a fine balance between epigenetic silencing and signaling is crucial ...

Unravelling the genetic mystery behind mitochondrial disease

September 15, 2016

Researchers from the Monash Biomedicine Discovery Institute in Melbourne have identified two new genes linked to a major cause of mitochondrial disease. Their research opens the way for better genetic diagnosis of the disease ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.